TrialBritish journal of clinical pharmacology2019

Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.

Masako Saito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.